GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (MEX:GSK N) » Definitions » 3-Year Sharpe Ratio

GSK (MEX:GSK N) 3-Year Sharpe Ratio : -0.75 (As of Jun. 28, 2025)


View and export this data going back to 2003. Start your Free Trial

What is GSK 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-06-28), GSK's 3-Year Sharpe Ratio is -0.75.


Competitive Comparison of GSK's 3-Year Sharpe Ratio

For the Drug Manufacturers - General subindustry, GSK's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's 3-Year Sharpe Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where GSK's 3-Year Sharpe Ratio falls into.


;
;

GSK 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


GSK  (MEX:GSK N) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


GSK 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of GSK's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK Business Description

Address
79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK Headlines

No Headlines